CARs and cancers: questions and answers
- PMID: 22538493
- DOI: 10.1182/blood-2012-02-410373
CARs and cancers: questions and answers
Abstract
In this issue of Blood, Till et al present 3 patients with relapsed B-cell lymphomas treated with autologous T cells genetically modified to express a CD20-targeted chimeric antigen receptor (CAR) demonstrating both safety and clinical efficacy.
Comment on
-
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.Blood. 2012 Apr 26;119(17):3940-50. doi: 10.1182/blood-2011-10-387969. Epub 2012 Feb 3. Blood. 2012. PMID: 22308288 Free PMC article.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources

